{"id":"colistimethate-sodium-cms","safety":{"commonSideEffects":[{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Neurotoxicity"},{"rate":null,"effect":"Bronchospasm"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Colistimethate sodium (CMS) is the inactive methane sulfonate salt of colistin that is converted to active colistin in vivo. Colistin is a polymyxin antibiotic that acts as a cationic detergent, binding to the lipopolysaccharide layer of gram-negative bacteria and disrupting membrane integrity, leading to bacterial cell death. It is primarily used against multidrug-resistant gram-negative organisms.","oneSentence":"Colistimethate sodium is a prodrug that is hydrolyzed to colistin, which disrupts bacterial cell membranes by binding to lipopolysaccharides and causing cell lysis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:06:38.118Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multidrug-resistant gram-negative bacterial infections"},{"name":"Cystic fibrosis-associated Pseudomonas aeruginosa infections"}]},"trialDetails":[{"nctId":"NCT06488794","phase":"PHASE2, PHASE3","title":"Nebulised Colistimethate Sodium to Prevent Pediatric Ventilator-associated Pneumonia","status":"NOT_YET_RECRUITING","sponsor":"University Hospital Fattouma Bourguiba","startDate":"2027-01-01","conditions":"Ventilator Associated Pneumonia","enrollment":400},{"nctId":"NCT06834971","phase":"NA","title":"Colistin Methanesulfonate Sodium Inhalation for Prophylaxis of Ventilator-Associated Pneumonia (CIVAP): A Prospective, Multicentre, Double-Blind, Randomized, Placebo-Controlled Trial","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2025-07-15","conditions":"Ventilator-Associated Pneumonia (VAP)","enrollment":508},{"nctId":"NCT06702943","phase":"","title":"Comparing Tigecycline Vs. Colistimethate in CNS Infections","status":"NOT_YET_RECRUITING","sponsor":"Ain Shams University","startDate":"2024-12-01","conditions":"Central Nervous System Infections","enrollment":70},{"nctId":"NCT05542446","phase":"PHASE4","title":"Pharmacokinetics of Colistin in Critically Ill Patients With Extracorporeal Membrane Oxygenation","status":"TERMINATED","sponsor":"St. Anne's University Hospital Brno, Czech Republic","startDate":"2022-09-01","conditions":"Colistin","enrollment":8},{"nctId":"NCT03460704","phase":"PHASE3","title":"Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium.","status":"TERMINATED","sponsor":"Zambon SpA","startDate":"2018-01-29","conditions":"Non Cystic Fibrosis Bronchiectasis","enrollment":287},{"nctId":"NCT03093974","phase":"PHASE3","title":"Efficacy and Safety of Inhaled CMS in Bronchiectasis Subjects With Chronic P. Aeruginosa Infection. (PROMIS-I)","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2017-06-06","conditions":"Non Cystic Fibrosis Bronchiectasis","enrollment":377},{"nctId":"NCT02288429","phase":"","title":"Evaluation of Pharmacokinetic and Pharmacodynamic Properties of Intravenous Colistimethate Sodium","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2013-09","conditions":"Colistin","enrollment":16},{"nctId":"NCT02452047","phase":"PHASE3","title":"Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-08-21","conditions":"Bacterial Infections","enrollment":50},{"nctId":"NCT01449838","phase":"PHASE1","title":"Phase I Study of Colistin Methanesulfonate Sodium","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-10-23","conditions":"Infections, Pseudomonas","enrollment":22},{"nctId":"NCT01845246","phase":"NA","title":"Multicentric Study About the Usefulness of Monitoring Plasma Levels of Colistin and Sodium Colistimethate in Patients With Infections Due to Multi-drug Resistant Gram Negative Bacilli, Treated With Colistin","status":"COMPLETED","sponsor":"Parc de Salut Mar","startDate":"2012-01","conditions":"Multidrug Resistant Gram Negative Bacterial Infections","enrollment":101}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Colistimethate sodium (CMS)","genericName":"Colistimethate sodium (CMS)","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Colistimethate sodium is a prodrug that is hydrolyzed to colistin, which disrupts bacterial cell membranes by binding to lipopolysaccharides and causing cell lysis. Used for Multidrug-resistant gram-negative bacterial infections, Cystic fibrosis-associated Pseudomonas aeruginosa infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}